Pharmex Of Japan To Set Up Drug Factory In Brunei
This article was originally published in PharmAsia News
Executive Summary
Tokyo-based generic drug exporter and distributor Pharmex Japan will build a drug manufacturing and packaging plant in Brunei. Pharmex also aims to sell its products to other Muslim countries after receiving Halal Products Certifications and achieve annual sales of ¥200 billion. The plant is to be completed in 2010 with an investment of ¥10 billion. The generic drug market in Islam Halal-certified countries is estimated to be around ¥1,800 billion. However, to receive certification, most drug capsules that use pig gelatin have to be reformulated, and doing so requires drug makers to apply for new approvals with regulatory authorities like Japan's Ministry of Health, Labor and Welfare. Pharmex plans to use the new plant to manufacture capsule drugs and drops and liquid drugs with syringes, and to ship drugs there for packaging. (Click here for more - Japanese language
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.